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Abstract:  
TNF-related apoptosis-inducing ligand (TRAIL), a
member of the TNF family, selectively induce apop-
tosis in various transformed cell lines but not in
almost-normal tissues. It is regulated by 2 death
receptors, TRAIL receptor 1 (TRAIL-R1) and TRAIL-
R2 and 2 decoy receptors, TRAIL-R3 and TRAIL-R4.
However, the determining factors of the sensitivity
to TRAIL-induced apoptosis are not clearly under-
stood. Herein, we investigated the expression of
TRAIL-R, c-FLIP, FADD-like interleukin-1β-converting
enzyme inhibitory protein, and TRAIL-induced apop-
tosis in human hepatocellular carcinoma (HCC) cell
lines.  Seven of ten HCC cell lines showed resis-
tance to TRAIL-induced apoptosis and five of seven
TRAIL-resistant cell lines became sensitive to TRAIL
by co-treatment with cycloheximide. In HCC cell
lines, their TRAIL resistance did not correlate with
the basal expression level of TRAIL receptors or c-
FLIP, however, in human tissues, TRAIL-R1 and
TRAIL-R2 expressions were notably decreased com-
pared to normal counterpart.  Cisplatin showed syn-
ergistic effect on TRAIL-induced apoptosis in most
HCC cell lines regardless of their p53 status and
TRAIL-R1 was induced by cisplatin treatment in cer-
tain cell lines. Inhibition of nuclear factor κ B (NF-κB)
by SN50, a peptide inhibitor of NF-κB activity, had no
effect on TRAIL-induced apoptosis in HCC cells.
These results suggest that (a) the majority of human
HCC cell lines are resistant to TRAIL-induced apop-
tosis and cycloheximide-sensitive short-lived anti-
apoptotic molecule(s) is responsible for this resis-
tance, (b) the expression of TRAIL-R1 and TRAIL-R2
is reduced in HCC tissues, and the increased expres-
sion of TRAIL-R1 may be a mechanism of cisplatin-
induced sensitization to TRAIL-induced apoptosis in
some HCC cells, and (c) the activation of NF-κB may
not be involved in the TRAIL resistance of HCC cells
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Introduction
TNF-related apoptosis-inducing ligand (TRAIL) is one of
the apoptosis-inducing molecules belonging to the
tumor necrosis factor (TNF) family (Wiley et al., 1995;
Pitti et al., 1996). Four different membrane-bound
receptors for TRAIL have been identified. Among these,
TRAIL-R1 (DR4) and TRAIL-R2 (DR5) are typical death
receptors, and belong to the death receptor family
containing a death domain in their cytoplasmic tails (Pan
et al., 1997a; Pan et al., 1997b; Screaton et al., 1997;
Sheridan et al., 1997; Walczak et al., 1997). However,
TRAIL-R3 (DcR1; TRID) and TRAIL-R4 (DcR2) are
decoy receptors that have no or short cytoplasmic tail
respectively, which lack a death domain (Degli-Esposti
et al., 1997a; Degli-Esposti et al., 1997b; Pan et al.,
1997a; Sheridan et al., 1997; Mongkolsapaya et al.,
1998; Pan et al., 1998). When TRAIL binds to its
receptors, TRAIL-R1 and TRAIL-R2 consign cells to the
apoptotic process, while TRAIL-R3 and TRAIL-R4
prevent apoptosis by competing with TRAIL-R1 or
TRAIL-R2 in the binding to TRAIL. Meanwhile, TRAIL-
R1, TRAIL-R2 and TRAIL-R4 are able to activate
nuclear factor-κB (NF-κB) (Chaudhary et al., 1997;
Degli-Esposti et al., 1997a; Schneider et al., 1997),
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and therefore suppress apoptotic process (Beg and
Baltimore, 1996; Van Antwerp et al., 1996; Wang et al.,
1996). In addition, osteoprotegerin, a soluble receptor
for TNF-related activation-induced cytokine (TRANCE),
also binds to TRAIL (Emery et al., 1998), and may act
as a third decoy receptor.
TRAIL had been considered as a candidate of the
selective anti-cancer drug (Ashkenazi et al., 1999;
Walczak et al., 1999), because it had been reported that
TRAIL induced apoptosis only in tumor cells but not in
normal cells. Initially, the deficiency of TRAIL-R3
expression in tumor cells was suspected as a mechanism
of tumor-specific TRAIL toxicity (Gura, 1997). However,
this decoy hypothesis is no longer accepted due to the
absence of a correlation between TRAIL sensitivity and
TRAIL-R3 expression (Griffith and Lynch, 1998; Griffith
et al., 1999a). Although the exact determinant of TRAIL
sensitivity is unclear, the extent of cellular FLICE
inhibitory protein (c-FLIP) expression (Griffith et al.,
1998; Kim et al., 2000) and the loss of FADD-like
interleukin-1β-converting enzyme (FLICE; caspase-8)
expression (Grotzer et al., 2000) have been raised as
another possible determining factors.
TRAIL has been implicated to play a role as an effector
molecule in the anti-tumor action of immune cells such as
T cells and monocytes (Thomas and Hersey; 1998;
Griffith et al., 1999b; Kayagaki et al., 1999) and also as an
anti-tumor effector molecule in surveillance of tumor
metastasis for natural killer cells in liver (Takeda et al.,
2001). To better understand the definitive role of TRAIL,
we examined human hepatocellular carcinoma (HCC) cell
lines for the sensitivity to TRAIL-induced apoptosis, and
the mRNA expression of TRAIL receptors and c-FLIP in
HCC cell lines and tissues. We also investigated the effect
of cycloheximide, cisplatin, and SN50, a peptide inhibitor
of NF-κB on the sensitivity to TRAIL-induced apoptosis for
the clarification of the TRAIL resistance mechanism in
HCC cells.
Materials and Methods
Reagents
Recombinant human TRAIL was obtained from R&D
Systems (Minneapolis, MN, USA). Cycloheximide,
cisplatin and 3-(4-,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) were obtained from Sigma
(St. Louis, MO, USA). NF-κB-specific inhibitor, SN50 is
a cell-permeable peptide containing nuclear localization
sequence of NF-κB p50 and the signal peptide of
Kaposi fibroblast growth factor (Lin et al., 1995). SN50
and SN50M, control peptide of SN50, were obtained
from Biomol (Plymouth Meeting, PA, USA).
Cell lines and cell culture
Hep G2, Hep 3B and PLC/PRF/5 were obtained from
the American Type Culture Collection (Rockville, MD,
USA). Hep G2.2.15 cells, stable transfectants of the
hepatitis B virus (HBV) genome into Hep G2 (Sells et
al., 1987), were also included. These cell lines were
grown in MEM containing 10% fetal calf serum (Gibco
BRL, Grand Island, NY, USA). SNU-182, SNU-354,
SNU-368, SNU-387, SNU-398, and SNU-449 were
obtained from the Korean Cell Line Bank (Seoul, Korea)
(Park et al., 1995), and were grown in RPMI 1640
containing 10% fetal calf serum. All media contained
100 U/ml of penicillin and 100 µg/ml of streptomycin.
Preparation of HCC tissues
HCC and adjacent non-tumorous tissues were obtained
immediately after surgical resection. The tissues were
rapidly frozen in liquid nitrogen and stored at -70oC until
RNA preparation (Shin et al., 1998).
MTT assay
Cell viability was assessed by MTT assay (Gerlier and
Thomasset, 1986). Briefly, 104 cells were seeded to 96-
well plate in 100 µl medium and left overnight to adhere.
Then, 100 µl medium containing recombinant TRAIL was
added. After 24 h, 50 µl of 2 mg/ml MTT solution was
added to each well and incubated for another 4 h at 37oC.
The plates were then centrifuged at 200 g for 10 min and
the supernatant was discarded. Then, 50 µl of dimethyl
sulfoxide was added to each well, and the plates were
shaken until the crystals dissolved. Reduced MTT was
then measured spectrophotometrically in a dual beam
microtiter plate reader at 570 nm with a 650 nm reference.
Analysis of oligonucleosomal DNA fragments
The formation of oligonucleosomal DNA fragments was
investigated using agarose gel electrophoresis (Jiang et
al., 1999). Briefly, cells were treated with TRAIL and/or
cycloheximide. After 24 h, both floating and adherent
cells were collected and resuspended in 250 µl TE
buffer. The suspensions were then mixed with an equal
volume of lysis buffer containing 20 mM EDTA, 0.05%
(v/v) Triton X-100 and 10 mM Tris⋅Cl, pH 8.0. After 30
min-incubation on ice, the lysates were centrifuged and
the fragmented DNA in supernatant was precipitated
with ethanol. DNA was resuspended in 20 µl TE buffer,
incubated subsequently with RNase A, and thereafter
with proteinase K. Electrophoresis was performed for at
70 V on 1.8% agarose gels. The gel was stained with
ethidium bromide and visualized with UV light.
RNA extraction and RNase protection assay (RPA)
Total cellular RNA was isolated from the HCC cells or
tissues with RNeasy kit (Qiagen, Santa Claris, CA,
USA). RPA was performed with RiboQuantTMmulti-probe
RPA kit (Pharmingen, San Diego, CA, USA) according
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32P-labeled antisense riboprobes were synthesized with
hAPO-3c template set, 2.75 mM ATP, GTP, CTP, 100
µCi [α-32P]-UTP (3000 Ci/mmol, NEN, Boston, MA,
USA) and 20 U T7 RNA polymerase. 32P-labeled
antisense riboprobes were hybridized with 10 µg of total
cellular RNA at 56oC for 16 h. After hybridization, 20 ng
of RNase A and 50 U of RNase T1 were added to digest
unhybridized RNA. Duplex RNA hybrids were loaded
onto 6% denaturing polyacrylamide gel containing 8 M
urea and visualized by autoradiography.
Semiquantitative RT-PCR
cDNA was synthesized from 5 µg of total cellular RNA
using 2 µg of random hexamer (Pharmacia, Uppsala,
Sweden), 1.25 mM dNTP (Boehringer Mannheim,
Mannheim, Germany) and 200 U M-MLV reverse tran-
scriptase (Gibco BRL). PCR was performed using 0.25
mM dNTP, 0.25 U Taq polymerase (Perkin Elmer,
Branchburg, NJ, USA), 10 pmole primer pairs, and cDNA
in a thermal cycler (Perkin Elmer). The following primer
pairs were used: TRAIL-R3: 5'-GAT CCC CAA GAC CCT
AAA GTT-3' and 5'-GGT TTC CAC AGT GGC ATT GGC-
3'; TRAIL-R4: 5'-AGG GAT GGT CAA GGT CAG TAA T-
3' and 5'-GAT GTC AGC GGA GTC AGC GTC A-3';
osteoprotegerin: 5'-GAA CCC CAG AGC GAA ATA CA-3'
and 5'-CGC TGT TTT CAC AGA GGT CA-3'; c-FLIP: 5'-
GGG AGA AGT AAA GAA CAA AG-3' and 5'-CGT AGG
CAC AAT CAC AGC AT-3'; β-actin: 5'-CGT GGG CCG
Figure 1. TRAIL-induced apoptosis in HCC cell lines. HCC cell lines were
treated with 200 ng/ml of TRAIL for 24 h and an MTT assay was performed
to evaluate cell viability. MCF7 and HeLa cells were used as the TRAIL-
sensitive positive controls. Each bar and vertical line represents the mean
and the standard error of the mean of four independent experiments.
Figure 2. Effect of cycloheximide on TRAIL-induced apoptosis in HCC cell lines. A. HCC cell lines were treated simultaneously with various combinations of
TRAIL and cycloheximide at the indicated concentrations for 24 h. MTT assay was performed to evaluate cell viability. Each dot and vertical line represents
the mean and the standard error of the mean of four independent experiments. B. HCC cell lines were treated with 100 ng/ml TRAIL and/or 1 µg/ml
cycloheximide (CHX) for 24 h. Oligonucleosomal DNA fragmentation was assessed by electrophoresis. Representative results of PLC/PRF/5 and SNU-182 are
shown.
 TRAIL-induced apoptosis in hepatoma cells 117AGG GGG G-3'. The PCR cycling conditions used were:
denaturation at 94oC for 30 s, annealing at 56oC for 30 s,
and extension at 72oC for 1 min. The optimal number of
PCR cycles for semiquantitation was previously
determined for each gene.
Results
Resistance to TRAIL and the effect of cycloheximide
on TRAIL-induced apoptosis in HCC cell lines
To investigate the sensitivity to TRAIL-induced apoptosis
in human HCC cell lines, ten HCC cell lines were
treated with 200 ng/ml TRAIL for 24 h and cell survival
was assessed by MTT assay. Three HCC cell lines,
PLC/PRF/5, SNU-368 and SNU-387, were sensitive to
TRAIL, and the other seven HCC cell lines were
resistant (Figure 1).
Cycloheximide, a protein synthesis inhibitor, was
found to sensitize cancer cells to TRAIL (Ahmad and
Shi, 2000; Leverkus et al., 2000) or FasL (Kim et al.,
2000). HCC cell lines treated with various combinations
of TRAIL and cycloheximide for 24 h was assessed for
cell survival. With 0.5 µg/ml cycloheximide, only Hep G2
and Hep G2.2.15 were sensitized to TRAIL. At 5 µg/ml
cycloheximide, Hep 3B, SNU-354, and SNU-449
became sensitized to TRAIL, but SNU-182 and SNU-
398 were still resistant (Figure 2A).
TRAIL-induced apoptosis was evaluated by oligo-
nucleosomal DNA fragmentation. Representative data
for PLC/PRF/5 and SNU-182 are shown in Figure 2B.
Typical DNA ladder formation was observed by
treatment with 100 ng/ml TRAIL in PLC/PRF/5 cells.
However, SNU-182 cells did not show DNA ladder
formation, even in the presence of cycloheximide. 
Expression of TRAIL receptors and c-FLIP in HCC
cell lines
To clarify the molecular determinants of TRAIL sensitivity
in HCC cell lines, the mRNA expression of TRAIL
receptors and c-FLIP in HCC cell lines was investigated.
The mRNA expressions of TRAIL-R1, TRAIL-R2 and
TRAIL-R3 were examined with RPA (Figure 3A). In HCC
cell lines, TRAIL-R2 was more abundantly expressed,
however the basal expression levels of pro-apoptotic
TRAIL-death receptors such as TRAIL-R1 and TRAIL-
R2 showed no correlation with the sensitivity to TRAIL.
The expression level of FLICE also showed no
correlation with the TRAIL sensitivity. Transcripts of
TRAIL-R3 could not be detected with RPA. The mRNA
expressions of the decoy receptors for TRAIL and the
intracellular FLICE inhibitor, c-FLIP, were examined by
semiquantitative RT-PCR (Figure 3B). TRAIL-R3 tran-
scripts were detected in several cell lines, however their
expression was very weak. TRAIL-R4 and c-FLIP were
expressed in all HCC cell lines and osteoprotegerin was
expressed in several cell lines. However, the expression
level of decoy receptors and c-FLIP also showed no
correlation with the TRAIL sensitivity. 
Expression of TRAIL receptors and c-FLIP in HCC
tissues
In order to enhance the detection sensitivity of the
expression level of TRAIL receptors and c-FLIP
between normal and cancer, RPA or semiquantitative
RT-PCR was used using RNA isolated from 4 pairs of
Figure 3. The mRNA expression of TRAIL receptors and c-FLIP in HCC cell
lines. A. The mRNA expression of TRAIL-R1, TRAIL-R2, TRAIL-R3 and
FLICE was examined by RPA in HCC cell lines. The expression of L32 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was examined for
the quantitation of internal control. B. The mRNA expression of TRAIL-R3,
TRAIL-R4, osteoprotegerin (OPG) and c-FLIP was examined by
semiquantitative RT-PCR.
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of the HCC tissues showed lower levels of TRAIL-R1
and TRAIL-R2 expressions in comparison with the
paired non-malignant liver tissues (Figure 4A and B).
Fas expression was also found to be lower in the HCC
tissues (Figure 4C) as previously reported (Shin et al.,
1998). In two cases (patient No. 2 and 4), TRAIL-R3
was remarkably expressed only in non-malignant liver
tissues (Figure 4D). TRAIL-R4, osteoprotegerin and c-
FLIP did not show any significant difference in HCC and
non-malignant liver tissues.
Synergistic effect of cisplatin on TRAIL-induced
apoptosis in HCC cells
Chemotherapeutic anti-cancer drugs sensitize many
tumor cells to TRAIL (Keane et al., 1999; Gibson et al.,
2000; Nagane et al., 2000). Examination of cisplatin effect
on TRAIL-induced apoptosis in HCC cell lines showed
that cisplatin induced synergistic effect on TRAIL-induced
apoptosis in all the HCC cell lines except SNU-387, in
which cisplatin showed additive effect (Figure 5). This
synergistic effect of cisplatin appeared even in SNU-182
and SNU-398, which were resistant to the TRAIL and
cycloheximide combination treatment. In addition, cisplatin
showed synergistic effect on TRAIL-induced apoptosis
regardless of p53 status of HCC cell lines: Hep 3B is
deficient of p53 and PLC/PRF/5, SNU-182, SNU-354,
SNU-368 and SNU-449 do not express wild type p53
(Kang et al., 1996; Jia et al., 1997).
To elucidate the mechanism of cisplatin-induced
Figure 4. The mRNA expression of TRAIL receptors and c-FLIP in HCC
tissues and paired non-malignant liver tissues. The mRNA expression of
TRAIL-R1, TRAIL-R2, and Fas was examined by RPA. The relative
intensities of TRAIL-R1 (A), TRAIL-R2 (B) and Fas (C) are presented in the
histogram. The relative intensity is the ratio of the band density of the gene
of interest to that of the internal control, GAPDH. The mRNA expression of
TRAIL-R3, TRAIL-R4, osteoprotegerin (OPG) and c-FLIP was examined by
semiquantitative RT-PCR (D).
Figure 5. Effect of cisplatin on TRAIL-induced apoptosis in HCC cell lines.
HCC cell lines were treated with 100 ng/ml TRAIL and/or 5 µg/ml cisplatin
(CP) for 24 h. MTT assay was performed to evaluate cell viability. Each bar
and vertical line represents the mean and the standard error of the mean of
four independent experiments. 
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stigated the changes in the mRNA expression of death-
mediating TRAIL receptors, TRAIL-R1 and TRAIL-R2
after cisplatin treatment in HCC cell lines. In Hep G2,
Hep G2.2.15, Hep 3B and SNU-449, the expression of
TRAIL-R1 was obviously increased by cisplatin
treatment (Figure 6). However, the expression of TRAIL-
R2, TRAIL receptor known as DNA damage-responsive
gene, was not markedly changed, although slight up-
regulation was shown in Hep 3B and SNU-449. The
increased expression of TRAIL-R1 or TRAIL-R2 was
independent of p53 status in HCC cell lines. 
No effect of NF-κB inhibitor, SN50 on TRAIL-induced
apoptosis in HCC cells
TRAIL-R1, TRAIL-R2 and TRAIL-R4 are able to
activate NF-κB (Chaudhary et al., 1997; Degli-Esposti
et al., 1997a; Schneider et al., 1997), and the
inhibition of NF-κB activity make cells sensitive to
TNF-α-induced apoptosis (Beg and Baltimore, 1996;
Van Antwerp et al., 1996; Wang et al., 1996). Thus,
the inhibition of NF-κB activity might induce cells
become sensitive to TRAIL.  SN50, a peptide inhibitor
of NF-κB, suppressed cell viability in the majority of
HCC cell lines without TRAIL (Figure 7A), however,
Figure 6. Effect of cisplatin on the mRNA expression of TRAIL-R1 and TRAIL-R2 in HCC cell lines. HCC cell lines were treated with (CP) or without (C) 5
µg/ml cisplatin for 12 h, and the mRNA expression of TRAIL-R1 and TRAIL-R2 was examined by RPA. The expression of L32 and GAPDH was examined
for the quantitation of internal control.
Figure 7. Effect of NF-κB inhibitor, SN50 on TRAIL-induced apoptosis in HCC cell lines. HCC cell lines were treated for 24 h with either SN50, a peptide
inhibitor of NF-κB, or SN50M, the control peptide (A). In the presence of 100 ng/ml TRAIL, HCC cell lines were treated with SN50 or SN50M for 24 h (B).
MTT assay was performed to evaluate cell viability. Each bar and vertical line represents the mean and the standard error of the mean of four independent
experiments. The increment of TRAIL-induced apoptosis by SN50 is no greater than the reduction of basal viability caused by SN50. 
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7B). These results suggest that NF-κB activation may
not be responsible for the resistance to TRAIL-
induced apoptosis in HCC cells. 
Discussion
The majority of HCC cell lines examined here showed
resistance to TRAIL despite the report that variety of
tumor cells have responded to TRAIL-induced apoptosis.
A similar finding of resistance to TRAIL-induced
apoptosis was reported on different HCC cell lines
(Yamanaka et al., 2000). TRAIL has been reported to
play a role as an effector molecule in the anti-tumor
action of immune cells such as T cells and monocytes
(Thomas and Hersey, 1998; Griffith et al., 1999b;
Kayagaki et al., 1999). Natural killer cells utilize TRAIL
as an anti-tumor effector molecule in surveillance of
tumor metastasis in liver (Takeda et al., 2001).
Augmention of TRAIL-induced apoptosis observed here
with cycloheximide and cisplatin suggest that anti-
apoptotic protein(s) with relatively short half-life such as
c-FLIP may be involved in the TRAIL resistance in HCC
cell lines. In the presence of a subtoxic level of
actinomycin D, a transcription inhibitor, TRAIL induced
significant apoptosis in HCC cell lines (Yamanaka et al.,
2000). However, the fact that two HCC cell lines were
still resistant to TRAIL even in the presence of
cycloheximide, may suggest that in those two cell lines
there might be another mechanism(s) for the resistance.
The augmentation of TRAIL-induced apoptosis by
chemotherapeutic drugs is a well-known phenomenon
(Keane et al., 1999; Gibson et al., 2000; Nagane et al.,
2000, Yamanaka et al., 2000). Such augmentation by
anticancer drugs was anticipated when TRAIL-R2 was
cloned as a p53-responsive gene (Wu et al., 1997). Our
results showed that synergistic effect of cisplatin on
TRAIL-induced apoptosis was independent of p53
status in HCC cell lines. Among the HCC cell lines used
in the present study, Hep 3B is deficient of p53 and
PLC/PRF/5, SNU-182, SNU-354, SNU-368 and SNU-
449 do not express wild type p53 (Kang et al., 1996; Jia
et al., 1997). It may be worthwhile to identify the
mechanism of cisplatins effect in these cell lines. The
mRNA expression of TRAIL-R1 was increased by
cisplatin treatment in several HCC cell lines, without any
correlation to their p53 status. The expression of Fas,
another death receptor, is up-regulated by cisplatin only
in HCC cell lines with wild-type p53 (Muller et al., 1997;
Jiang et al., 1999). However, up-regulation of TRAIL-R1
may not be a sole explanation for synergistic cell killing,
because there were some cell lines that showed more
effective synergistic cell death without up-regulation of
TRAIL-R1 expression. Direct or indirect insult of cisplatin
on mitochondria after DNA damage could be additional
mechanisms for the synergistic cell death (Choi et al.,
2000).
In TNF-α-induced apoptosis, inhibition of NF-κB
activity induced cells to become sensitive to apoptosis
(Beg and Baltimore, 1996; Van Antwerp et al., 1996;
Wang et al., 1996) and TRAIL-R1, TRAIL-R2 and
TRAIL-R4 were able to activate NF-κB (Chaudhary et
al., 1997; Degli-Esposti et al., 1997a; Schneider et al.,
1997). The inhibition of NF-κB activity made cells
sensitive to TRAIL-induced apoptosis (Jeremias et al.,
1998; Goke et al., 2000; Franco et al., 2001; Oya et al.,
2001). However, we found that NF-κB inhibitor, SN50
treatment of human HCC cells caused no effect on the
TRAIL-induced cellular apoptosis. Such discrepancy
may be due to the different specificity of the NF-κB
inhibitor used. We used the NF-κB-specific inhibitor,
SN50, which is a cell-permeable peptide containing
nuclear localization sequence of NF-κB p50 and the
signal peptide of Kaposi fibroblast growth factor (Lin et
al., 1995), however, the others used the non-degradable
IκBα mutant (Jeremias et al., 1998; Franco et al., 2001;
Oya et al., 2001) or sulfasalazine (Goke et al., 2000).
Another possible cause of this discrepancy may be the
difference of cell types. Our results suggested that NF-
κB activation may not be responsible for TRAIL
resistance in HCC cells and this conclusion could be
supported by the previous report that TRAIL resistance
was found to be unrelated to TRAIL-induced NF-κB
activity in HCC cell lines (Yamanaka et al., 2000),
however this result should be confirmed with various
NF-κB-inhibiting systems. 
When TRAIL-R3, the first decoy receptor, was cloned,
the expression of TRAIL-R3 was considered to be the
major determinant of sensitivity in TRAIL-induced
apoptosis (Gura, 1997). However, no concordant
correlation was found between TRAIL-R3 expression
and resistance to TRAIL-induced apoptosis (Griffith and
Lynch, 1998; Griffith et al., 1999a). The expression level
of c-FLIP has been focused as a mechanism for TRAIL
resistance (Griffith et al., 1998; Kim et al., 2000), and
recently, the loss of FLICE expression was considered
as another possible mechanism (Grotzer et al., 2000).
Our results revealed that no consistent correlations
were found between the resistance of HCC cells to
TRAIL to the expression levels of any TRAIL receptors,
c-FLIP or FLICE. It is likely that there may be no
universal determining factor and each HCC cell line may
have specific mechanisms in this regard. The
examination of TRAIL receptors and c-FLIP expression
in HCC tissues and in the non-malignant liver showed
that the expression of TRAIL-R1 and TRAIL-R2 was
down-regulated in HCCs tissues compared with the
adjacent non-malignant liver. Such findings are similar
to that of Fas, another death-mediating receptor (Shin et
al., 1998). 
In conclusion, the majority of human HCC cells were
 TRAIL-induced apoptosis in hepatoma cells 121found resistant to TRAIL, suggesting that this resistance
may be requisite for HCC formation. In addition,
cycloheximide-sensitive short-lived anti-apoptotic mo-
lecule(s) was responsible for the resistance to TRAIL-
induced apoptosis, but activation of NF-κB may not be
involved in this resistance. Furthermore, the expression
of TRAIL-R1 and TRAIL-R2 was found reduced in HCC
tissues, and the increased expression of TRAIL-R1 may
be the mechanism of cisplatin-induced sensitization to
TRAIL-induced apoptosis in some HCC cells.
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